The Immunology Podcast cover image

Ep. 29: “Immuno-Oncology Therapeutics” Featuring Dr. Michael Alonso

The Immunology Podcast

00:00

Embrace Your Challenges, Right?

Bolt: We found that we encountered extremely high levels of anti drug antibody, right? Because again, what did we actually do? We tied an immune stimulant to an antibody. So obviously, you know, if that antibody has immunogenicity, you run a real risk of amplifying that response. And I remember Richard Miller, who's the co founder of Corvus with pharma cyclics, huge in the development of retoxumab. He looked at us and he said, look, that one's not going to hunt. Go get a new one. That was devastating data to a company with series A funding.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app